He Ben-Zhen, Wang Liang
Department of Radiology, The Affiliated Hospital of Shaoxing University (Shaoxing Municipal Hospital), Shaoxing, Zhejiang, People's Republic of China.
Clin Transl Oncol. 2025 May;27(5):1933-1942. doi: 10.1007/s12094-024-03743-7. Epub 2024 Oct 6.
Reproductive cancers, such as ovarian, cervical, and endometrial carcinomas, have a poor prognosis in metastatic stages. Researchers are continuously seeking improved and safer methods to target cancer-related oncoproteins, addressing the limitations of current treatments, including their limited effectiveness, drug resistance, and off-target effects. Recent advancements in understanding the molecular mechanisms involved in the progress of reproductive cancers have provided valuable insights into potential targeted therapies. By engaging with oncoproteins and co-chaperones, heat-shock protein 90 (HSP90) regulates signaling networks and fixes protein folding errors in cancer cells. The potential of HSP90 inhibition as cancer-targeted treatments is underscored by the continuous discovery and testing of novel HSP90-targeted molecules for their antitumor properties in preclinical and clinical settings. Therefore, this study aims to shed light on the mechanism and recent research breakthroughs of HSP90, as well as provide an in-depth review of their therapeutic potential in reproductive cancers.
生殖系统癌症,如卵巢癌、宫颈癌和子宫内膜癌,在转移阶段预后较差。研究人员一直在不断寻找更有效、更安全的方法来靶向与癌症相关的癌蛋白,以解决当前治疗方法的局限性,包括疗效有限、耐药性和脱靶效应。最近在理解生殖系统癌症进展所涉及的分子机制方面取得的进展,为潜在的靶向治疗提供了有价值的见解。通过与癌蛋白和共伴侣蛋白相互作用,热休克蛋白90(HSP90)调节信号网络并修复癌细胞中的蛋白质折叠错误。在临床前和临床环境中,针对新型HSP90靶向分子的抗肿瘤特性不断有新发现和测试,这凸显了抑制HSP90作为癌症靶向治疗的潜力。因此,本研究旨在阐明HSP90的作用机制和最近的研究突破,并对其在生殖系统癌症中的治疗潜力进行深入综述。